The EAGLE Trial: Why Lens Removal Can Beat Laser

If you are farsighted and over 50, there is a good chance an eye doctor has already said two words to you: “narrow angles.” Maybe it came with a recommendation for a laser iridotomy, a small hole in the iris to relieve pressure. Maybe it came with nothing more than “we’ll keep an eye on it.”

What almost nobody tells you is that the largest randomized trial ever run on this problem did not test a laser against a drop. It tested removing the natural lens, the same operation I perform for refractive lens exchange, against the laser. And the lens surgery won.

That study is called the EAGLE trial. It was published in The Lancet in 2016, it was funded by the UK Medical Research Council rather than a lens company, and it is the single most important piece of evidence behind why I so often recommend refractive lens exchange to farsighted patients with crowded angles. This post explains what the trial actually did, what the numbers mean, and where it does and does not apply to you.

What the EAGLE trial set out to answer

The question was simple. When a patient over 50 is diagnosed with primary angle closure (drainage angle blocked, pressure up) or primary angle-closure glaucoma (the same, plus damage to the optic nerve), what should the first treatment be?

For decades the answer was laser peripheral iridotomy, then pressure-lowering drops, then glaucoma surgery if those failed. The laser opens a tiny channel so fluid can bypass the pupil. But it does nothing about the reason the angle is crowded in the first place, which in most of these eyes is a natural lens that has grown thick with age and is pushing the iris forward.

The EAGLE investigators asked a more radical question. If the lens is the problem, why not remove it, replace it with a thin artificial lens, and open the angle mechanically? They called it clear-lens extraction, because the lens came out before it had become a cataract (Azuara-Blanco et al., The Lancet, 2016).

What the EAGLE trial found at three years

Three years after treatment, the lens-extraction group had lower eye pressure, better patient-reported quality of life, and better value for money than the laser group. Those were the three primary endpoints, and lens surgery won all three (Azuara-Blanco et al., The Lancet, 2016).

The headline difference in pressure was modest on paper, about 1.2 mm Hg. The real story is what it took to get there. A later analysis of the same patients found that 90% of the lens-extraction group had controlled pressure without any additional surgery at three years, versus 67% of the laser group. More striking: 66% of the lens-extraction patients were controlled with no drops at all, versus 18% after laser. Patients who had lens surgery were roughly ten times more likely to remain drop-free and surgery-free (Mitchell et al., British Journal of Ophthalmology, 2023).

In the trade press coverage of the original presentation, the investigators reported that 24 laser patients went on to need glaucoma surgery compared with one lens-extraction patient (Healio Ocular Surgery News, 2016). Irreversible vision loss occurred in one lens-surgery patient and three standard-care patients. No serious adverse events were recorded in either group (Azuara-Blanco et al., The Lancet, 2016).

The authors’ conclusion was direct: clear-lens extraction “showed greater efficacy and was more cost-effective than laser peripheral iridotomy, and should be considered as an option for first-line treatment.”

The guideline writers agree. The American Academy of Ophthalmology’s 2026 Preferred Practice Pattern for angle-closure disease lists lens extraction as “an effective treatment for patients with PACG and PAC with markedly elevated IOP,” cites the EAGLE finding that lens-extraction patients were “10 times more likely to maintain IOP control without medications,” and states that earlier lens extraction, “even if the lens is not visually significant, can be considered for the initial management” of these patients (Gedde et al., Ophthalmology, 2026).

Why removing the lens works where the laser cannot

Picture the anatomy of a farsighted eye. It is short from front to back. The anterior chamber, the fluid-filled space between the cornea and the iris, is shallow. The drainage angle, where that fluid exits the eye, is narrow. The natural lens sits just behind the iris, and it never stops growing. By your 50s it is noticeably thicker than it was at 20, and in a short eye there is nowhere for that extra bulk to go except forward, into the iris, into the angle.

A laser iridotomy punches a relief valve through the iris. The thick lens is still there, still pushing.

Lens extraction removes the lens entirely and replaces it with an implant a fraction of its thickness. The chamber deepens. The iris falls back. The angle opens. One study that imaged the front of the eye before and after each treatment in 122 patients with narrow angles found that after lens extraction every eye had an open angle on examination, with a deeper chamber and lower pressure. After laser alone, chamber depth and pressure did not change significantly, and more than half the eyes still had at least one section of angle that remained closed (Yan et al., Graefe’s Archive for Clinical and Experimental Ophthalmology, 2019).

That is the mechanism. The laser treats a symptom of crowding. Lens surgery treats the crowding.

What the laser does well, and where it falls short

I want to be fair to the laser, because it still has a place. A separate landmark study, the Zhongshan Angle Closure Prevention trial in China, followed 889 people who had narrow angles but no pressure problem and no nerve damage, the group doctors call angle-closure suspects. Each person had laser in one eye and nothing in the other. Over six years, the laser roughly halved the chance of progressing to angle closure. But the risk was so low to begin with that the authors concluded routine preventive laser for everyone with narrow angles was not justified (He et al., The Lancet, 2019). At 14 years, a third as many laser-treated eyes had progressed, though those eyes also showed slightly more cataract and slightly higher pressure than their untreated partners (Yuan et al., Ophthalmology, 2023).

The Academy’s guideline puts it plainly: most angle-closure suspects will never develop angle closure or glaucoma, and following them without a laser is an accepted alternative (Gedde et al., Ophthalmology, 2026).

So the picture that emerges from the two trials together is this. For a narrow angle that is not yet causing trouble, a laser offers a modest benefit and watchful waiting is reasonable. For an angle that has already pushed the pressure up or damaged the nerve, the EAGLE trial says lens removal is the stronger first move.

And there is a third group neither trial enrolled, which happens to be most of the farsighted patients who walk into my office: people in their 50s and 60s with crowded angles, reading glasses in every room, and a growing frustration with distance vision, who have never been told their anatomy is part of the conversation. For them, the lens surgery that was a glaucoma treatment in EAGLE is the same lens surgery that fixes their vision. One procedure, two problems.

The honest limits of the EAGLE trial

A single trial, even a good one, never answers everything. Three cautions.

First, the EAGLE trial enrolled people with established disease: pressure of 30 or higher, or glaucoma damage already present. It did not enroll healthy farsighted eyes with narrow angles. When I recommend lens exchange to a patient in that healthier group, I am extrapolating from the mechanism and from the Zhongshan data, not quoting a trial that studied them directly. I say so in the consultation. If your pressure is already elevated or your nerve already shows damage, that is a glaucoma conversation first, and timing matters.

Second, lens surgery is surgery. The EAGLE trial recorded no serious adverse events, but any lens-based procedure carries small risks, including retinal detachment at roughly 1 in 500 for refractive lens exchange, a risk that is higher in long, nearsighted eyes and lower in the short eyes of farsighted patients (Passaro et al., British Journal of Ophthalmology, 2025). A laser iridotomy is quick, office-based, and carries almost none of that.

Third, and this is the part refractive surgeons should be most candid about: the EAGLE eyes did not land on their refractive target as reliably as a routine lens exchange would. Only 59% were within half a diopter of the predicted prescription at three years, and 85% within one diopter (Day et al., British Journal of Ophthalmology, 2018). Short, crowded eyes are harder to measure, and scarring in the angle can shift where the implant settles. That is not a reason to avoid the procedure. It is a reason to choose the lens carefully.

Why I often pair this with the Light Adjustable Lens™ (LAL®)

Refractive predictability is exactly the problem the Light Adjustable Lens was designed to solve. Its power can be fine-tuned with painless light treatments after the eye has healed, so the lens power is set based on how the eye actually sees rather than on a pre-operative prediction. In our own 2025 series of 137 eyes, 98% finished within 0.50 D of target and 91% saw 20/20 or better; individual results vary, and you can read the full data on our results page.

For a short, farsighted eye with a narrow angle, where the EAGLE cohort showed the measurement problem in black and white, that adjustability is the difference between “the pressure is better” and “the pressure is better and I see clearly without glasses.” A trifocal or extended depth of focus lens remains an option for the right eye; the choice depends on your anatomy, your lifestyle, and your goals, and no single lens is right for everyone.

A recent example: narrow angles, prior LASIK, and two different lenses

Last week I operated on one of my closest friends, who has given me permission to share his story. He is farsighted, and his exam showed narrow, occludable angles in both eyes: the exact anatomy the EAGLE trial was built around, caught before it had caused any damage. He had two choices for his angles: a laser iridotomy, or refractive lens exchange, which would open the angles and fix his vision in the same operation. He chose the lens. Because I also treat glaucoma, I wanted an independent opinion, so I sent him to a glaucoma specialist to confirm the findings. The specialist agreed that lens exchange was the right call.

Then the lens choice got interesting, because his two eyes had different histories. His left eye had hyperopic LASIK 20 years ago. Prior corneal surgery makes standard lens-power calculations less predictable, so that eye received the Light Adjustable Lens, which lets me set the final power after the eye has healed. His right eye had never been touched. It measured well for a trifocal: low higher-order aberrations, an angle alpha under 0.5 mm, and no dry eye. That eye received an enVista Envy™ trifocal. Two eyes, two different lenses, one blended range of vision: the mix-and-match approach I use whenever one lens cannot do a whole person’s visual life.

Two days after surgery, before his light treatments had even begun, he texted me: “Have an all day board meeting today. Read 100 pages of board materials without reading glasses yesterday. Insane!” The 100 pages were read on the first day after surgery.

One patient is one patient, and individual results vary. But his case is the whole post in miniature: the anatomy EAGLE studied, the decision EAGLE informed, and lens choices made eye by eye.

Who this is NOT for

Not every narrow angle calls for surgery, and not every farsighted patient is a lens exchange candidate. I steer patients elsewhere when:

• The angle is narrow (but not occludable) and the pressure is normal, the nerve is healthy, the prescription is low, and the patient is happy in glasses. Monitoring, with or without a laser, is a reasonable path, and I will say so.
• There is significant macular disease, an irregular cornea, or severe dry eye. These limit what any premium lens can deliver.
• The patient is under 45 with a stable prescription and a healthy, adequately thick cornea. Corneal options such as LASIK or PRK may serve them better, although I will note that corneal surgery does nothing for a crowded angle.
• Angle-closure glaucoma is already advanced. Lens surgery may still be part of the plan, but it is a glaucoma plan first.

Candor is not a sales technique. It is how a surgeon who performs every consultation and every operation himself keeps the yeses credible.

Frequently asked questions

What was the EAGLE trial?

The EAGLE trial was a randomized study of 419 patients published in The Lancet in 2016. It compared removing the natural lens (clear-lens extraction) against laser iridotomy as the first treatment for primary angle closure and angle-closure glaucoma. After three years, lens removal produced lower eye pressure, better quality of life, and better cost-effectiveness.

Can refractive lens exchange treat narrow angles?

Yes, removing the natural lens and replacing it with a thin implant deepens the anterior chamber and opens the drainage angle. In the EAGLE trial that effect controlled pressure better than laser iridotomy. Whether it is the right choice for your eye depends on your pressure, your nerve, your prescription, and your goals.

Is a laser iridotomy still recommended for narrow angles?

Yes, in selected patients. For narrow angles without raised pressure or nerve damage, the Zhongshan trial found a modest protective benefit from laser, and many of those eyes do well with monitoring alone. For angles that have already raised pressure or caused damage, the EAGLE trial favored lens removal.

Does being farsighted raise my risk of angle-closure glaucoma?

Farsighted eyes are typically shorter with shallower chambers and narrower angles, and the natural lens thickens with age, so the risk rises over time. Hyperopia, a shallow anterior chamber, a shorter eye, and a thicker lens are all listed risk factors for angle-closure disease in the American Academy of Ophthalmology’s 2026 practice guideline.

Will my vision be as predictable as a normal lens exchange?

Short eyes with narrow angles are harder to measure, and the EAGLE cohort showed only 59% of eyes within half a diopter of target. This is one reason I often recommend the Light Adjustable Lens for these eyes, because its power can be adjusted after surgery.

Does refractive lens exchange prevent cataracts too?

Yes. The artificial lens cannot develop a cataract, so a patient who has refractive lens exchange will never need cataract surgery later.

Related reading

• Refractive Lens Exchange in Newport Beach (Pillar)
• Farsighted After 50? Why RLE Often Fits Better Than LASIK
• Dysfunctional Lens Syndrome
• Light Adjustable Lens
• EVO ICL vs. Refractive Lens Exchange
• Vision Correction After 50: A Surgeon Compares All Options

Find out what your angle is telling you

If you are farsighted, over 50, and have ever heard the words “narrow angles,” the most useful next step is a full evaluation that looks at the drainage angle, the chamber depth, and the lens itself, not just a glasses prescription. I perform every consultation personally.